Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study

J Am Acad Dermatol. 2021 Feb;84(2):552-554. doi: 10.1016/j.jaad.2020.06.038. Epub 2020 Jun 18.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Placebos / administration & dosage
  • Placebos / adverse effects
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Placebos
  • secukinumab